Parenteral norovirus vaccine formulations
The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.
1. A composition comprising a genogroup I Norovirus virus-like particle (VLP) and a genogroup II Norovirus VLP, wherein the genogroup I and genogroup II Norovirus VLPs are present in the composition in different amounts, and wherein the genogroup I Norovirus VLP is present in the composition at an amount of about 15 μg and the genogroup II Norovirus VLP is present in the composition at an amount of about 50 μg.
2. The composition of claim 1 , wherein the genogroup I Norovirus VLP is GI.1.
3. The composition of claim 1 , wherein the genogroup II Norovirus VLP is GII.4.
4. The composition of claim 1 , wherein the composition further comprises an adjuvant.
5. The composition of claim 4 , wherein the adjuvant is not a bacterially-derived exotoxin.
6. The composition of claim 4 , wherein the adjuvant is selected from the group consisting ofmonophosphoryllipid A (MPL), synthetic lipid A, lipid A mimetics or analogs, flagellin, aluminum salts, cytokines, saponins, muramyl dipeptide (MDP) derivatives, CpG oligos, lipopolysaccharide (LPS) of gram-negative bacteria, polyphosphazenes, emulsions, virosomes, cochleates, poly(lactide-co-glycolides) (PLG) microparticles, poloxamer particles, microparticles, liposomes, oil-in-water emulsions, MF59, squalene, 3DMPL, and QS21.
7. The composition of claim 1 , wherein the composition comprises a buffer selected from the group consisting of L-histidine, imidazole, succinic acid, tris, citric acid, bis-tris, pipes, mes, hepes, glycine amide, and tricine.
8. The composition of claim 7 , wherein the buffer is L-histidine or imidazole.
9. A method for inducing protective immunity to Norovirus in a subject, the method comprising administering to the subject the composition of claim 1 .
10. The method of claim 9 , wherein the composition elicits at least a three-fold increase in Norovirus -specific serum antibody titer as compared to the titer in the subject prior to administration of the composition.
11. The method of claim 9 , wherein the composition elicits a seroresponse rate in the subject of at least 60%.
12. The method of claim 11 , wherein the composition elicits seroresponse rate in the subject of at least 65%.
13. The method of claim 11 , wherein the seroresponse rate is an IgA or pan Ig seroresponse rate.
14. The method of claim 9 , wherein the composition is administered to the subject by a route selected from the group consisting of mucosal, intranasal, intramuscular, intravenous, subcutaneous, intradermal, subdermal, and transdermal routes of administration.
15. The method of claim 14 , wherein the composition is administered intramuscularly.